Astrazeneca Soliris News Today

Samsung Bioepis, a biosimilar developer under Samsung Group, said Monday that the company's rare blood disease treatment, Epysqli, has won marketing authorization from South Korea's medicine authorities. Epysqli, a biosimilar close to AstraZeneca's Soliris (eculizumab), is a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disease where red blood cells prematurely break apa...

FDA approval of Novartis’s Fabhalta makes the drug the first approved oral therapy for rare blood disorder paroxysmal nocturnal hemoglobinuria. With clinical data showing superiority versus two infused AstraZeneca drugs, Novartis’s pill is well-positioned to take market share from those blockbuster products.

The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.

BioPharma

In this article, we discuss the 11 safe healthcare stocks for a retirement stock portfolio.

The company finds some protection against measures aimed to cut industry drug prices.

AstraZeneca (NASDAQ:AZN) announced an agreement to buy Alexion Pharmaceuticals (NASDAQ:ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. Based on AstraZenecas closing price on Friday, Alexion shareholders are in line to receive about $175 per share.  Regulatory hurdles that come with big international mergers are expected to keep this one from completing until the third quarter of 2021. Based on yesterdays closing prices for both stocks, t...